Startup
Sector:
Biotech
08/12/2025
New York, NY USA
Gameto
completed $44 million Series C Round funding. Investors include
Overwater Ventures (lead), Insight Partners, RA Capital Management, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investments, PAGS Group, Portfolia, Pontiva Healthcare Partners.
The financing brings Gameto's total capital raised to an industry-leading $127 million, reflecting both the potential of the company's platform and the speed with which it has progressed its scientific vision toward final stages of clinical development. The Series C funding enables Gameto to complete the ongoing Phase 3 trial for its lead program, Fertilo, and file for regulatory approvals globally. Fertilo is already cleared to commercialize many ex-U.S. jurisdictions and is currently used in clinics in Peru, Mexico and Australia, with additional clearances in Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay. Five babies have been born with Fertilo so far and over 20 pregnancies have been recorded.
About
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.
Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that.
Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones.
Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases.
Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
